- S&P 5007,561.67−0.40%
- Nasdaq 10027,943.74−1.22%
- NVDA$162.85−2.01%
- AAPL$356.27+0.39%
- MSFT$523.88+0.17%
- GOOGL$295.77−0.98%
- AMZN$266.66−0.29%
- META$641.69+2.90%
- TSLA$390.22−1.82%
- AVGO$347.01−4.76%
- AMD$534.06−8.75%
- MU$778.31−2.52%
Stock news
317 stories
Investment case changesSummit Therapeutics Inc. (NASDAQ: SMMT) Adds Detail to Lung-Cancer Survival DataSummit Therapeutics Inc. (NASDAQ: SMMT) reported fuller ivonescimab survival results. The global finding improved, but Western data remain inconclusive. SMMT · OptimistFi Research Desk · 
Investor guidesDamora Therapeutics, Inc. (NASDAQ: DMRA) Stock Is Down 13.8%: The Investment CaseThe company has $540.5 million to develop blood-cancer treatments. A rival's head start makes the next patient results especially important. DMRA · OptimistFi Research Desk · 
Market narrative auditsWhy Asif Suria Is Watching TransMedics Group, Inc. (NASDAQ: TMDX)Asif Suria spotted a director turning from seller to buyer. The filings reveal one clean $62-to-$129.82 round trip before David Weill's new $81.63 purchase. TMDX · OptimistFi Research Desk · 
Market narrative auditsForgent Power Solutions, Inc. (NYSE: FPS) Generates Cash as Sales SurgeForgent Power Solutions, Inc. (NYSE: FPS) kept about $43 million after quarterly capital spending. A bigger order book brings the next funding test. FPS · OptimistFi Research Desk · 
Market narrative auditsiShares 20+ Year Treasury Bond ETF Adds Little Yield for More RiskThe fund offers only 0.13 percentage points more SEC yield than its 10-to-20-year sibling as Treasury yields reach 19-year highs. TLT · OptimistFi Research Desk · 
Market narrative audits5E Advanced Materials Buys Producing Borates Assets in BankruptcyThe deal could add current production, but 8.3 million consideration shares equal 20% of the company's March share count. FEAM · OptimistFi Research Desk · 
Market narrative auditsMicrosoft Proposes Safety Rules for Its Future AI ModelsMicrosoft's draft code would guide its own AI models from 2027. Current models are not trained on it, limiting what investors can conclude today. MSFT · OptimistFi Research Desk · 
Market narrative auditsEos's $87 Million Advance Doesn't Prove Full ProductionThe DOE advance reimburses prior eligible spending. Eos says its second battery line is still ramping toward designed capacity. EOSE · OptimistFi Research Desk · 
Investment case changesScholar Rock Wins FDA Approval for Spinal Muscular Atrophy DrugIsembyld targets muscle loss alongside existing treatment. Scholar Rock's first launch now hinges on insurance coverage, patient uptake and safety. SRRK · OptimistFi Research Desk · 
Market narrative auditsIBEX's 2027 Outlook Targets Growth but Little Margin ExpansionIBEX forecasts fiscal 2027 revenue of $700 million to $715 million. New-client training and delivery costs remain a risk to profit. IBEX · OptimistFi Research Desk · 
Market narrative auditsAlphabet's Hassabis Backs AI Pacing as Capital Spending DoublesDemis Hassabis supports the direction of slower frontier progress, but Alphabet's latest filing still shows accelerating infrastructure investment. GOOGL · OptimistFi Research Desk · 
Market narrative auditsSkyworks Extends Qorvo Debt Swap With 92% of Notes TenderedQorvo bondholders have offered about 92% of eligible debt. Participation rose just 0.37 percentage points in ten days, and the merger still has to close. SWKS · OptimistFi Research Desk ·
SMMT · OptimistFi Research Desk · 
TMDX · OptimistFi Research Desk · 
FEAM · OptimistFi Research Desk · 
EOSE · OptimistFi Research Desk · 
SRRK · OptimistFi Research Desk · 
IBEX · OptimistFi Research Desk ·